Sionna Therapeutics Announces Restructuring, 46% Workforce Cut & Option Repricing

What Happened

• Sionna Therapeutics (SION) filed an 8-K disclosing a Board-approved restructuring on September 9, 2026 to focus on its SION-451 and SION-2222 dual combination program and extend cash runway. The plan includes a workforce reduction of approximately 46% and wind-down of the SION-719 add-on program. The Company also announced it will advance SION-451/SION-2222 into a Phase 2a proof-of-concept trial and issued a press release on September 14, 2026.
• As part of the restructuring, Chief Business Officer Caroline Stark Beer was terminated without cause effective September 15, 2026. The Board reallocated executive roles effective September 16, 2026: Charlotte McKee (CMO) adds Head of R&D, Elena Ridloff (CFO) adds Chief Business Officer, and Jennifer Fitzpatrick (Chief Legal Officer) adds Head of Program Management. No compensation changes were made for these role changes.

Key Details

• Estimated restructuring and related charges: approximately $6.4 million total, consisting of about $5.3M in employee severance/post-employment benefits, $0.7M contract close-out costs (SION-719), and $0.4M stock-based compensation expense.
• Timing: workforce reductions and vendor wind-down are expected to be substantially completed by the end of Q3 2026; related cash payments may continue into Q4 2026.
• Option repricing approved on September 9, 2026 and effective September 17, 2026: employee-held options with exercise prices above $18.00 (and certain $18.00 grants to recent non-exec hires) will have exercise prices reduced to the Nasdaq closing price on the repricing date. Repriced options revert to original price if exercised before the end of an 18-month retention period (or certain specified events). Repricing does not require stockholder approval.
• Severance for the terminated CBO is subject to the Company’s Severance and Change in Control Plan and an executed release; health/dental coverage extension approved from up to 9 months to up to 12 months if elected.

Why It Matters

• The restructuring is material because it reduces headcount nearly in half and incurs a near-term charge (~$6.4M), both of which affect cash use and near-term operating capacity. Investors should note the Company’s stated aim to preserve cash and prioritize the SION-451/SION-2222 clinical program and extend runway.
• Executive role consolidations and the CBO departure change operational leadership but did not include pay changes; option repricing is intended to retain remaining employees after the reduction, which may affect future equity dilution and employee incentives.
• The move toward a Phase 2a proof-of-concept trial for the dual combination program is the Company’s primary clinical focus going forward — progress, trial design, timing and results will be key milestones for investors.